Jill Rasmussen, MD, Medical Advisor, ConSynance, presented CSTI-500: A Promising Treatment for Prader-Willi Syndrome (PWS) at IPWSO’s Research and Clinical Trials Update meeting on Thursday the 7th of September, 2023.
CSTI 500 is a triple re-uptake inhibitor of the serotonin, dopamine and norepinephrine. The compound is in entering Phase 2 development for the treatment of hyperphagia and behavioural symptoms associated with Prader-Willi Syndrome (PWS). CSTI-500’s unique balance of pharmacology is different from other re-uptake inhibitors, and other compounds in development for PWS.
In accordance with our Policy and Code of Practice, IPWSO does not promote individual trials or the use of specific medications. [ Ссылка ]
The information contained in the multimedia content (video content) posted, represents the views and opinions of the original creators, and whilst IPWSO requests presenters to use content that is evidence-based and peer reviewed, the video content does not necessarily represent the views of IPWSO. The mere appearance of video content on this site does not constitute an endorsement by IPWSO or its affiliates of such content. The content has been made available for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. IPWSO hereby disclaims any and all liability to any party for any direct, indirect, implied, punitive, special, incidental, or other consequential damages arising directly or indirectly from any use of the video content, which is provided as is, and without warranties.
For more videos about Prader-Willi syndrome subscribe for free to our IPWSO channel: [ Ссылка ]
